Literature DB >> 17375873

Role of molecular markers in diagnosis and prognosis of renal cell carcinoma.

Guido Martignoni1, Matteo Brunelli, Stefano Gobbo, Andrea Remo, Vincenzo Ficarra, Paolo Cossu-Rocca, Maurizio Pea, Marco Chilosi, Fabio Menestrina, Liang Cheng.   

Abstract

It has been demonstrated that different renal cell neoplasms have characteristic morphologic and genetic features. Histologic subtyping of renal epithelial neoplasms has been shown to be of prognostic value; therefore they must be correctly classified. Although adequate sampling and a good understanding of the morphologic features usually minimize diagnostic errors, the use of immunohistochemical and chromosomal analysis on formalin-fixed, paraffin-embedded tissues can be necessary. These techniques can facilitate diagnosis on small biopsies, which are increasingly obtained from renal masses. An immunohistochemical panel including CD10, parvalbumin, AMACR, CK7 and S100A1 seems the most promising; fluorescence in situ hybridization analysis using centromeric probes to evaluate the gains and losses of the chromosomes can be helpful in selected cases. A wide variety of molecular markers have been examined, but further research is required to prove their value as prognostic tools.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375873

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  9 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

Review 2.  Should Small Renal Masses Be Biopsied?

Authors:  Ricardo R N Leão; Ardalan E Ahmad; Patrick O Richard
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

3.  Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria.

Authors:  B Walter; A Hartmann; F Hofstädter; K Junker; H Moch; S Bertz; S Denzinger; W Otto; M Gajda; C G Stoehr
Journal:  Virchows Arch       Date:  2012-02-17       Impact factor: 4.064

4.  TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.

Authors:  Anna Caliò; Stefano Marletta; Matteo Brunelli; Serena Pedron; Sofia Canete Portillo; Diego Segala; Elena Bariani; Stefano Gobbo; George Netto; Guido Martignoni
Journal:  Virchows Arch       Date:  2022-08-18       Impact factor: 4.535

5.  Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.

Authors:  Jay Amin; Bo Xu; Shervin Badkhshan; Terrance T Creighton; Daniel Abbotoy; Christine Murekeyisoni; Kristopher M Attwood; Thomas Schwaab; Craig Hendler; Michael Petroziello; Charles L Roche; Eric C Kauffman
Journal:  Clin Cancer Res       Date:  2018-05-11       Impact factor: 12.531

6.  AMACR expression in colorectal cancer is associated with left-sided tumor localization.

Authors:  Andreas Marx; Philipp Simon; Ronald Simon; Martina Mirlacher; Jakob R Izbicki; Emre Yekebas; Jussuf T Kaifi; Luigi Terracciano; Guido Sauter
Journal:  Virchows Arch       Date:  2008-08-19       Impact factor: 4.064

7.  S100A1 expression characterizes terminally differentiated superficial cells in the urothelium of the murine bladder and ureter.

Authors:  Fairouz Qasrawi; Max Meuser; Finja Lehnhoff; Marjenna Schulte; Andreas Kispert
Journal:  Histochem Cell Biol       Date:  2022-06-01       Impact factor: 2.531

8.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.

Authors:  Florian R Fritzsche; Kirsten Wassermann; Monika Jung; Angelika Tölle; Ilka Kristiansen; Michael Lein; Manfred Johannsen; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  BMC Cancer       Date:  2008-06-26       Impact factor: 4.430

9.  GPC3 reduces cell proliferation in renal carcinoma cell lines.

Authors:  Marina Curado Valsechi; Ana Beatriz Bortolozo Oliveira; André Luis Giacometti Conceição; Bruna Stuqui; Natalia Maria Candido; Paola Jocelan Scarin Provazzi; Luiza Ferreira de Araújo; Wilson Araújo Silva; Marilia de Freitas Calmon; Paula Rahal
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.